Antiresorptive drugs (ARD), including bisphosphonates, monoclonal antibodies, SERMs and others, are widely used in treatment of various bone diseases, such as osteoporosis, metastatic bone disease, osteogenesis imperfecta, Paget’s disease. These medications work by inhibiting bone resorption, and as a result increasing bone strength and preventing fractures. Although their use is associated with many clinical benefits, there’ve been cases of developing medication-related osteonecrosis of the jaw (MRONJ). While the pathogenesis of MRONJ remains incompletely understood, it is believed to result from a disruption in bone remodeling process, specifically the inhibition of osteoclast function. Moreover, infections caused by Actinomyces spp. have been implicated in the development of MRONJ, although their role in the disease remains unclear. This review brings out connection between ARDs, bone remodeling and oral microbiology, providing a comprehensive overview of the current understanding of MRONJ and its clinical implications.

Key words: antiresorptive drugs, MRONJ, actinomycosis.